Targeting endothelial ligands: ICAM-1/alicaforsen, MAdCAM-1

W Reinisch, K Hung… - Journal of Crohn's …, 2018 - academic.oup.com
Specific blockade of the endothelial ligands intercellular adhesion molecule-1 [ICAM-1] and
mucosal addressin cell adhesion molecule [MAdCAM] involved in leukocyte recruitment to …

[HTML][HTML] Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

WJ Sandborn, S Vermeire, L Peyrin-Biroulet… - The Lancet, 2023 - thelancet.com
Background Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

S Vermeire, WJ Sandborn, S Danese, X Hébuterne… - The Lancet, 2017 - thelancet.com
Background PF-00547659 is a fully human monoclonal antibody that binds to human
mucosal addressin cell adhesion molecule-1 (MAdCAM-1) to selectively reduce lymphocyte …

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

S Danese, S Vermeire, P Hellstern, R Panaccione… - Gut, 2019 - gut.bmj.com
Objective Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's
disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported …

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

W Reinisch, J Panés, S Khurana, G Toth, F Hua… - Gut, 2015 - gut.bmj.com
Objective Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC.
Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the …

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study

WJ Sandborn, SD Lee, D Tarabar, E Louis, M Klopocka… - Gut, 2018 - gut.bmj.com
Objective This phase II, randomised, double-blind, placebo-controlled clinical trial was
designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal …

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a …

L Chang, BD Cash, A Lembo… - …, 2023 - Wiley Online Library
Background Olorinab is a highly selective, peripherally acting, full agonist of cannabinoid
receptor 2. This study assessed the efficacy and safety of olorinab to treat abdominal pain in …

Challenges and opportunities in IBD clinical trial design

MC Dubinsky, R Collins, MT Abreu, V Jairath… - …, 2021 - gastrojournal.org
The International Organization for the Study of In-flammatory Bowel Disease held a single-
day meeting focused on challenges and opportunities in trial design. The meeting included …

Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab [SHP647] for the treatment of ulcerative colitis: the open-label study …

W Reinisch, WJ Sandborn, S Danese… - Journal of Crohn's …, 2021 - academic.oup.com
Abstract Background and Aims Ontamalimab, a fully-human monoclonal antibody targeting
MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in …

[HTML][HTML] Assessing cranial nerves in physical therapy practice: findings from a cross-sectional survey and implication for clinical practice

F Mourad, G Lopez, F Cataldi, F Maselli, L Pellicciari… - Healthcare, 2021 - mdpi.com
Background and objective: Serious pathologies of the neck can potentially result in cranial
nerve palsy. Knowledge about cranial nerve examination (CNE) seems sparse, and its use …